PMID: 9545830Apr 18, 1998Paper

Successful syngeneic peripheral blood stem cell transplantation for protracted myelosuppression after chemotherapy in a patient with acute myelogenous leukemia

[Rinshō ketsueki] The Japanese journal of clinical hematology
K MoritaI Tanaka

Abstract

Acute myelogenous leukemia (M2) with translocation of 8;21. Was diagnosed in 61-year-old man. He was successfully treated and obtained complete remission. After consolidation therapy, myeloid suppression and maturation arrest at the myelocyte level were recognized. Following intensive chemotherapy, he received rhG-CSF-mobilized peripheral blood stem cell transplantation (PBSCT) from an identical twin because he had life threatening infectious events and protracted myelosuppression. Transplantation of 2.5 x 10(6)/kg CD34+ cells resulted in a rapid normal tri-lineage hematologic reconstitution. Syngeneic PBSCT appears to be a substitute for syngeneic bone marrow transplantation in certain situations.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.